Baidu
map

2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌

2019-12-05 加拿大泌尿外科协会 Can Urol Assoc J. 2020 Feb;14(2):17-23.

2019年12月,加拿大泌尿外科协会(CUA)联合加拿大泌尿肿瘤组(CUOG)共同发布了转移性单纯去势和去势敏感型前列腺癌的管理指南,转移性前列腺癌仍是一种无法治愈的疾病,本文主要针对转移性单纯去势和去势敏感型前列腺癌的管理提出指导见。

中文标题:

2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌

英文标题:

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

发布机构:

加拿大泌尿外科协会

发布日期:

2019-12-05

简要介绍:

2019年12月,加拿大泌尿外科协会(CUA)联合加拿大泌尿肿瘤组(CUOG)共同发布了转移性单纯去势和去势敏感型前列腺癌的管理指南,转移性前列腺癌仍是一种无法治愈的疾病,本文主要针对转移性单纯去势和去势敏感型前列腺癌的管理提出指导见。

 

拓展指南:前列腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌)] GetToolGuiderByIdResponse(projectId=1, id=990851c0018610fc, title=2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌, enTitle=Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer., guiderFrom=Can Urol Assoc J. 2020 Feb;14(2):17-23., authorId=null, author=, summary=2019年12月,加拿大泌尿外科协会(CUA)联合加拿大泌尿肿瘤组(CUOG)共同发布了转移性单纯去势和去势敏感型前列腺癌的管理指南,转移性前列腺癌仍是一种无法治愈的疾病,本文主要针对转移性单纯去势和去势敏感型前列腺癌的管理提出指导见。 , cover=, journalId=null, articlesId=null, associationId=1160, associationName=加拿大泌尿外科协会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Dec 05 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019年12月,加拿大泌尿外科协会(CUA)联合加拿大泌尿肿瘤组(CUOG)共同发布了转移性单纯去势和去势敏感型前列腺癌的管理指南,转移性前列腺癌仍是一种无法治愈的疾病,本文主要针对转移性单纯去势和去势敏感型前列腺癌的管理提出指导见。 </P> <P> </P>拓展指南:<strong>与<font color=red>前列腺癌</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=b11861c001839356" title="2019 多学科共识文件:转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测" target=_blank>2019 多学科共识文件:转移性激素敏感和转移性去势抵抗性前列腺癌患者的监测</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=1ef331c0018353a5" title="转移性前列腺癌化疗中国专家共识(2019版)" target=_blank>转移性前列腺癌化疗中国专家共识(2019版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=0fd8d1c0018235ca" title="2019 ESTRO-ACROP共识指南:影像学指导局限性前列腺癌的放射治疗" target=_blank>2019 ESTRO-ACROP共识指南:影像学指导局限性前列腺癌的放射治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=daa061c001808aba" title="68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南" target=_blank>68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=6d9ec1c00180312d" title="2019 CUA/CUOG指南:去势抵抗性前列腺癌的管理" target=_blank>2019 CUA/CUOG指南:去势抵抗性前列腺癌的管理</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E5%89%8D%E5%88%97%E8%85%BA%E7%99%8C" target=_blank>有关前列腺癌更多指南</a></ul>, tagList=[TagDto(tagId=781, tagName=前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7540, appHits=172, showAppHits=26, pcHits=1954, showPcHits=6425, likes=43, shares=1, comments=2, approvalStatus=1, publishedTime=Sun Feb 09 01:07:54 CST 2020, publishedTimeString=2019-12-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Feb 09 01:07:54 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:20:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌)])
2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=892842, encodeId=08b6892842e0, content=非常受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT6cbtvT3o7icibpicpHiamGPlBJiaToQoNdqibGHpfiaibg9Mx79wgicJ7lM43SzmXibeZI8oIEh2vZvnhUtw/132, createdBy=744b2171805, createdName=answer.col, createdTime=Sun Oct 18 14:23:59 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379084, encodeId=e2dd3e908435, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6dc05268402, createdName=148193d7m29(暂无昵称), createdTime=Mon Feb 10 16:00:27 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-10-18 answer.col

    非常受用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=892842, encodeId=08b6892842e0, content=非常受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT6cbtvT3o7icibpicpHiamGPlBJiaToQoNdqibGHpfiaibg9Mx79wgicJ7lM43SzmXibeZI8oIEh2vZvnhUtw/132, createdBy=744b2171805, createdName=answer.col, createdTime=Sun Oct 18 14:23:59 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379084, encodeId=e2dd3e908435, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6dc05268402, createdName=148193d7m29(暂无昵称), createdTime=Mon Feb 10 16:00:27 CST 2020, time=2020-02-10, status=1, ipAttribution=)]
    2020-02-10 148193d7m29(暂无昵称)

    学习了

    0

Baidu
map
Baidu
map
Baidu
map